The article by McCahill et al, entitled, "Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10" (J Clin Oncol 10.1200/JCO.2012.42.4044), was published online August 6, 2011 with an error.
In the Introduction section, the second sentence of the last paragraph was given as: "Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) combined with the anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody bevacizumab has demonstrated an improvement in OS in patients with metastatic CRC.12"
Whereas it should have been: "Irinotecan, fluorourcacil, and leucovorin combined with the anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody bevacizumab has demonstrated an improvement in OS in patients with metastatic CRC.12"
This has been corrected as of September 10, 2012. The authors apologize for the mistake.